Form 4: Former Aurinia Pharmaceuticals Director, R. Hector MacKay-Dunn, Reports Change in Beneficial Ownership
SEC Filing
R. Hector MacKay-Dunn, a former director of Aurinia Pharmaceuticals Inc., filed a Form 4 indicating a change in beneficial ownership of the company's securities.
Summary
- On September 20, 2024, R. Hector MacKay-Dunn, a former director of Aurinia Pharmaceuticals Inc., filed a Form 4 with the SEC.
- The filing pertains to changes in beneficial ownership of Aurinia Pharmaceuticals Inc. securities.
- The earliest transaction date reported is September 9, 2024.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing, indicating a change in ownership but not necessarily reflecting positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for individuals with insider access to publicly traded companies, providing transparency into their transactions and holdings.
Stakeholder Impact
- Shareholders may be interested in changes in ownership by insiders as an indicator of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 09/09/2024 | Earliest transaction date |
| 09/20/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.